Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Iratumumab Stories

2009-05-27 07:00:00

-Clinical study planned for relapsed / refractory acute myelogenous leukemia- PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1338, for the treatment of patients with acute myelogenous leukemia (AML). MDX-1338 is a fully human antibody that targets CXCR4, a chemokine receptor found on the surface of many cancer cells,...

2009-05-26 15:00:00

PRINCETON, N.J., May 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a conference call and live webcast at 4:00 p.m. Eastern Time on Tuesday, June 2, 2009. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex will provide an update and recent highlights from Medarex's pipeline. The webcast of the live event and archive can be accessed through the Investor Relations section of Medarex's website at www.medarex.com. To access the...

2009-05-05 15:00:00

PRINCETON, N.J., May 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Bank of America and Merrill Lynch Health Care Conference at 4:00 p.m. Eastern Time on Tuesday, May 12, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event. About Medarex Medarex is a biopharmaceutical...

2009-04-29 08:00:00

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a conference call and live webcast at 8:30 a.m. Eastern Time on Thursday, April 30, 2009 to review Medarex's business updates and financial results for the first quarter of 2009. To access the call live, please dial 1-877-397-0272 (U.S./Canada) or 1-719-325-4882 (international). The webcast can be accessed through the Investor Relations section of Medarex's website at www.medarex.com. A...

2009-04-20 07:00:00

PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced preliminary data from an ongoing Phase 1 clinical trial of MDX-1401 in patients with relapsed or refractory Hodgkin's lymphoma (HL) that demonstrated both clinical and immunological activity signals. MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers. Results...

2009-03-18 15:00:00

PRINCETON, N.J., March 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference at 11:20 a.m. Eastern Time on Thursday, March 26, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event. About Medarex...

2009-02-19 15:00:00

PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to announce its 2008 fourth quarter and year-end results on Wednesday, February 25, 2009 by press release after the financial markets close. Following the release, Medarex's management will host a conference call and live webcast at 4:30 p.m. Eastern Time. To access the call live, please dial 1-866-804-6925 (U.S./Canada) or...

2009-01-06 15:00:00

PRINCETON, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) on Tuesday, January 13, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event. About Medarex Medarex is...

2008-12-08 07:00:00

PRINCETON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Hodgkin's lymphoma (HL) as well as other CD30-expressing cancers. MDX-1401 demonstrated almost a doubling in potency and efficacy in cell lines when compared to MDX-060. The improved potency and...

2008-12-03 06:00:00

PRINCETON, N.J., Dec. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the RBC Capital Markets Healthcare Conference at 3:30 p.m. Eastern Time on Wednesday, December 10, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event. About Medarex Medarex is a...